This trial demonstrated that Ozempic®, a GLP-1 receptor agonist, significantly reduces the risk of progression in chronic kidney disease and cardiovascular mortality in patients with type 2 diabetes.
Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.